114 
1 MR. LIBERMAN: Members of the Committee, I am 
2 pleased to have this opportunity to appear here today and 
3 participate in this hearing. I shall try to confine my 
4 comments to three areas, and I shall try to keep my 
5 comments brief. 
6 My first comments concern the certification of 
7 HV 2 and HV 3 systems. The criteria for certification, and 
g I am referring to Section II-D on page 33075 of the Federal 
g Register , that are described, cannot be practically applied 
10 to nonbacterial systems. Specific criteria, I believe, 
11 should be developed which relate to tissue culture and 
12 other eukaryotic host systems. I will use Saccharomyces 
13 cerevisiae , brewers yeast, as an example. 
14 Both the National Science Foundation and the 
15 American Cancer Society have approved recombinant DNA 
16 projects with Saccharomyces cerevisiae as a host, and as 
17 far as I am aware, NIH has not. I believe that specific 
18 criteria must be developed in conjunction with other 
19 grant agencies to avoid problems where various agencies 
20 can move independently in reviewing recombinant projects. 
21 My next comments concern the definition of 
22 recombinant DNA itself, and what I would really like to 
23 do is ask questions of the Panel here, as well as the 
24 audience, to think about, because I don't know the answer. 
25 I would like to ask the distinguished 
[206] 
